---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Epcoritamab-bysp - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/epcoritamab-bysp
version: v1
---

# Epcoritamab-bysp - NCI

# Epcoritamab-bysp

Placeholder slot

(EP-koh-RIH-tah-mab)

Epcoritamab-bysp works by bringing healthy T cells (immune cells that help kill cancer cells) and lymphoma cells close together so the T cells can more effectively kill the lymphoma cells. It does this by binding to a protein called CD3 on healthy T cells and a protein called CD20 on B cells (the immune cells that are cancerous in B-cell lymphomas). Epcoritamab-bysp is a type of targeted therapy drug called a bispecific T-cell engager (BiTE).

US Brand Name(s)

Epkinly

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a&audience=consumer)

## Use in Cancer

Epcoritamab-bysp
is approved to treat adults with:

- **[Diffuse large B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=428286&version=Patient&language=English)** (DLBCL) or **[high-grade](/Common/PopUps/popDefinition.aspx?id=45710&version=Patient&language=English) [B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=444967&version=Patient&language=English).**
- **[Follicular lymphoma](/Common/PopUps/popDefinition.aspx?id=428287&version=Patient&language=English).**

Epcoritamab-bysp is used in patients with cancer that has come back or did not get better after at least two lines of systemic therapy.

These uses are approved under FDAâ€™s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that epcoritamab-bysp provides a clinical benefit in these patients.

Epcoritamab-bysp
is also being studied in the treatment of other types of
cancer.

## More About Epcoritamab-bysp

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/798973) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Epcoritamab-bysp](https://medlineplus.gov/druginfo/meds/a623023.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas](https://www.cancer.gov/news-events/cancer-currents-blog/2023/large-b-cell-lymphoma-axi-cel-zuma-7-trial)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Epcoritamab-bysp](https://www.cancer.gov/research/participate/clinical-trials/intervention/C163022) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
